Table 2.
Outcomes of the included studies
| Study (year) | Revisional surgery | Operative time (min) | Sample (n) | Leaks (n, %) | Bleeding (n, %) | Marginal ulcer (n, %) | EWL% | TWL% | T2DM resolution (%) | HTN resolution (%) | GERD on follow-up (%) | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiappeta (2019) | OAGB | 79 ± 36 | 34 | 0 (0%) | 0 (0%) | 0 (0%) | 29 ± 13 | 15.8 ± 7.8 | 100% | 66.7% | 11.8% | 9 |
| RYGB | 98 ± 24 | 21 | 0 (0%) | 0 (0%) | 1 (4.8%) | 22 ± 18 | 10.3 ± 7.6 | 60% | 0% | 4.8% | ||
| Rayman (2021) | OAGB | - | 144 | 2 (1.4%) | 2(1.4%) | 0 (0%) | 58.7 | 32 ± 9 | - | - | 17.4% | 9 |
| RYGB | - | 119 | 1 (1.7%) | 3 (2.5%) | 0 (0%) | 44.2 | 27 ± 9 | - | - | 7.6% | ||
| Felsenreich (2022) | OAGB | - | 13 | 0 (0%) | 0 (0%) | 0 (0%) | 80.3 ± 23.7 | 39.5 ± 11.5 | - | - | 28.9% | 9 |
| RYGB | - | 45 | 0 (0%) | 0 (0%) | 0 (0%) | 79.8 ± 34.1 | 37.7 ± 14.6 | - | - | 53.8% | ||
| Rheinwalt (2022) | OAGB | 168 ± 7.2 | 55 | 2 (3.6%) | 0 (0%) | 0 (0%) | 50 | 24 ± 2.6 | 92% | 92% | 13.34% | 8 |
| RYGB | 201 ± 6.8 | 68 | 4 (5.9%) | 2 (2.9%) | 0 (0%) | 40 | 18 ± 3.0 | 100% | 89% | 11.1% | ||
| Wilczyński (2022) | OAGB | - | 47 | 0 (0%) | 1 (2.12%) | 3 (6.4.%) | 84.04 ± 18.81 | 21.81 ± 12.48 | 97.3% | 27.3% | 28.6% | 8 |
| RYGB | - | 33 | 0 (0%) | 1 (3%) | 4 (12.1%) | 72.95 ± 20.3 | 18.39 ± 11.85 | 33.3% | 30% | 60% | ||
| Hany (2022) | OAGB | 85.6 ± 18.6 | 80 | 0 (0%) | 1 (1.25%) | 0 (0%) | -* | -* | 75% | 68% | - | 8 |
| RYGB | 104.9 ± 13.7 | 80 | 0 (0%) | 1 (1.25%) | 2 (2.5%) | -* | -* | 71% | 75% | - |
NOS Newcastle–Ottawa Scale. T2SM type 2 diabetes. HTN hypertension. *Hany et al. reported weight loss as %EBMIL